- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04174599
Trial to Compare the Efficacy and Safety of F-627 and GRAN® (F-627)
A Phase III, Multi-Center, Randomized, Open-Label, Active-Controlled Trial to Compare the Efficacy and Safety of F-627 and GRAN® in the Prophylactic Treatment for Chemotherapy-Induced Neutropenia
Study Overview
Detailed Description
Protocol Number: SP11631 Study Stage: Phase III Study Population Female patients with breast cancer will be enrolled to receive at least 4 cycles of EC chemotherapy, that is: epirubicin 100 mg/m2 and cyclophosphamide 600 mg/m2.
Study Design: A multi-center, randomized, open-label, active-controlled phase III clinical trial Site Number: 14 sites(planned) , 12 sites(actual) Subject Number: 240
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Beijing
-
Peking, Beijing, China, 100142
- Peking University Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Willing to sign the informed consent form and able to comply with protocol requirements;
- 18-75 years old;
- Female postoperative patients with breast cancer who require adjuvant chemotherapy, and are planned to receive at least 4 cycles of EC chemotherapy, namely epirubicin 100 mg/m2 + cyclophosphamide 600 mg/m2;
- ECOG performance status ≤ 2;
- Absolute neutrophil count (ANC) ≥ 2.0 × 109/L, hemoglobin (Hb) ≥ 11.0 g/dL, and platelet (PLT) ≥ 100 × 109/L prior to enrollment;
- Hepatic and renal functions: Total bilirubin ≤ 1.5 × ULN, ALT and AST ≤ 2.5 × ULN, serum creatinine ≤ 1.5 × ULN;
- Left ventricular ejection fraction > 50%;
- Women without child-bearing potential, i.e., women who have had menopause for at least 1 year or who have undergone sterilization (bilateral tubal ligation, double oophorectomy or hysterectomy); patients with child-bearing potential should agree to take appropriate contraceptive measures, including condoms, spermicidal condoms, foams, gels, contraceptive barrier, intrauterine devices (IUD), and contraceptives (oral or injection), starting from 1 month before the start of the study until 30 days after the end of the study.
Exclusion Criteria:
- Radiation therapy within 4 weeks prior to enrollment;
- Patients with breast cancer who have received neoadjuvant chemotherapy before surgery;
- Prior bone marrow or stem cell transplant;
- With other malignant tumors other than breast cancer;
- Patients who have received a treatment with recombinant human granulocyte colony stimulating factor within 6 weeks prior to randomization;
- Diagnosed with acute congestive heart failure, cardiomyopathy, or myocardial infarction by clinical diagnosis, ECG or other approaches;
- With any disease that may cause splenomegaly;
- With acute infection, chronic active Hepatitis B within 1 year (unless patients tested negative for HBsAg prior to enrollment), or Hepatitis C;
- Women in pregnancy or breastfeeding;
- Known HIV positive or AIDS;
- With active tuberculosis (TB); history of TB exposure, unless negative for tuberculin test; TB patients undergoing treatment; or suspected TB evaluated by chest x-ray;
- With sickle cell anemia;
- With alcohol or drug abuse that may affect the compliance with the study;
- With known hypersensitivity to granulocyte colony stimulating factor or excipients;
- Have received any other investigational drug within 1 month or 5 half-lives of the investigational drugs prior to enrollment (whichever is longer);
- Patients with diseases or symptoms unsuitable for participating in the trial. For example, the study drugs may compromise the health of the patient or the assessment of adverse events may be affected.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: F-627
Subjects will receive F-627 (20 mg/dose, s.c.) on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
|
Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
|
Active Comparator: GRAN®
Subjects will receive GRAN® [5 μg/kg/day, s.c., once daily (± 4 h) up to 2 weeks or until neutrophil count returns to 5.0 ×109/L] on day 3 of each cycle, i.e., 48 ±4 h after the start of chemotherapy.
|
Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The efficacy of F-627 versus GRAN® in the first cycle of prophylactic treatment in subjects with breast cancer receiving chemotherapy, as assessed by the number of days in which ANC < 1.0 × 109/L in cycle 1
Time Frame: At the end of cycle 1(each cycle is 21 days).
|
The primary endpoint is the duration (days) of grade 3 or 4 (moderate and severe) neutropenia in cycle 1, that is, the number of days in which ANC < 1.0 × 109/L in cycle 1.
|
At the end of cycle 1(each cycle is 21 days).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incidence of grade 3 or 4 neutropenia as assessed by ANC(ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively)
Time Frame: through study completion, an average of 21 days.
|
The incidence rate of grade 3 or 4 neutropenia (ANC < 1.0 × 109/L and ANC< 0.5 × 109/L, respectively)
|
through study completion, an average of 21 days.
|
durations (days) of grade 3 or 4 neutropenia as assessed by ANC(ANC < 1.0 × 109/L and ANC < 0.5 × 109/L, respectively)
Time Frame: in cycles 2-4, at the end of cycle 4(each cycle is 21 days.)
|
The durations (days) of grade 3 or 4 neutropenia (ANC < 1.0 × 109/L and < 0.5 × 109/L, respectively)
|
in cycles 2-4, at the end of cycle 4(each cycle is 21 days.)
|
incidence and duration (days) of grade 4 neutropenia are all as assessed by ANC(ANC < 0.5 × 109/L)
Time Frame: through study completion, an average of 21 days.
|
The incidence and duration (days) of grade 4 neutropenia (ANC < 0.5 × 109/L)
|
through study completion, an average of 21 days.
|
overall duration (days) of grade 3 or 4 neutropenia as assessed by ANC(ANC < 1.0 × 109/L and ANC < 0.5 ×109/L, respectively)
Time Frame: through study completion, in overall 4 cycles(each cycle is 21 days).
|
The overall duration (days) of grade 3 or 4 neutropenia (ANC < 1.0 × 109/L and ANC< 0.5 × 109/L, respectively)
|
through study completion, in overall 4 cycles(each cycle is 21 days).
|
The incidence and duration (days) of grade 2 or above neutropenia are all assessed by ANC (ANC < 1.5 × 109/L)
Time Frame: through study completion, an average of 21 days.
|
The incidence and duration (days) of grade 2 or above neutropenia (ANC < 1.5 × 109/L) in each cycle.
|
through study completion, an average of 21 days.
|
Incidence of febrile neutropenia (FN) (defined as ANC < 1.0×109/L; a single measurement of body temperature > 38.3°C or a temperature ≥ 38.0 °C sustained over 1 h)
Time Frame: 8 months
|
Incidence rate of febrile neutropenia (FN) (defined as ANC < 1.0×109/L; a single measurement of body temperature > 38.3 °C or a temperature ≥ 38.0 °C sustained over 1 hr)
|
8 months
|
ANC nadir
Time Frame: through study completion, an average of 21 days.
|
The time (days) of ANC nadir recovers to 2.0 × 109/L
|
through study completion, an average of 21 days.
|
The neutrophil count nadir from day 3 to day 13 of cycle 1
Time Frame: day 3 to day 13 of cycle 1(each cycle is 21 days).
|
The ANC nadir from day 3 to day 13 of cycle 1
|
day 3 to day 13 of cycle 1(each cycle is 21 days).
|
the time(days)of ANC nadir returns to 2.0 × 109/L
Time Frame: through study completion, an average of 21 days.
|
The time (days) of ANC nadir recovers to 2.0 × 109/L
|
through study completion, an average of 21 days.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the potential immunogenicity of F-627 by testing anti-F-627 antibodies inserum
Time Frame: 8 months
|
To evaluate the immunogenic potential of F-627 by testing serum anti-F-627 antibodies.
|
8 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Zhimin Shao, Doctor, Fudan university Shanghai cancer centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- SP11631
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
Baylor Breast Care CenterRecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer InvasiveUnited States
-
Innocrin PharmaceuticalCompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the BreastUnited States
Clinical Trials on F-627
-
EVIVE BiotechnologyCompletedBreast Cancer | NeutropeniaUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingColorectal Cancer | Pancreatic CancerChina
-
EVIVE BiotechnologyCompletedBreast Cancer | NeutropeniaUnited States
-
EVIVE BiotechnologyCompletedBreast Cancer | NeutropeniaUnited States
-
EVIVE BiotechnologySun Yat-sen University; Fudan UniversityCompleted
-
Aspen Medical ProductsTerminated
-
EVIVE BiotechnologyZhejiang Cancer Hospital; Fudan University; RenJi Hospital; Henan Cancer Hospital; Tongji Hospital and other collaboratorsCompleted
-
University of AlbertaSuspendedLow Back Pain | Magnetic Resonance Imaging | Bone Marrow Edema | Brace | Modic ChangesCanada
-
University of AlbertaAmerican Orthotic and Prosthetic AssociationSuspendedPain | Emergencies | Low Back Pain | Brace | Health Care ResourcesCanada
-
Clinique Romande de ReadaptationRecruitingHand Injuries and DisordersSwitzerland